Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3691 Efficacy of 177Lu-octreotate in biliary duct neuroendocrine tumor

Introduction: We report the case of a 69-year-old woman presenting a biliary duct neuroendocrine tumor, diagnosed in 2003 treated by extrahepatic biliary tract resection.

Conference:

Presenting Author:

Authors: Kelly A, Otman H, Petorin C, Perret-Boire S, Chanchou M,

Keywords: 177Lu-octreotate, biliary duct neuroendocrine tumor,

#3626 Long-term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu-octreotate peptide radionuclide therapy

Introduction: PRRT has shown favourable results in NETs. Long-term safety and efficacy data for 177Lu-Octreotate PRRT, particularly in combination with chemotherapy, is lacking.

Conference:

Presenting Author: Ransom D

Authors: Ransom D, Kennedy K, Turner J, Macdonald W, Boardman G,

Keywords: PRRT, long term, chemotherapy, leukaemia, myelodysplasia, renal,

#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma

Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Davi' M

Authors: Zambon G, Cosaro E, Cingarlini S, Trombetta M, Landoni L,

Keywords: pasireotide, malignant insulinoma, hypoglycemia,

#1904 Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy

Introduction: Paragangliomas (PGL) are a heterogeneous group of rare tumours that can express high numbers of somatostatin receptors on their cell surface and can be targeted with peptide receptor radionuclide therapy (PRRT) using the radiolabelled somatostatin analogue [lutetium-177-DOTA-Tyr3-]octreotate (177Lu-octreotate).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Smit Duijzentkunst D

Authors: Smit Duijzentkunst D, Kwekkeboom D,

Keywords: PRRT, paragangliomas,

#1711 Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours

Introduction: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy with 177Lu-octreotate (PRRT) are validated therapies in patients with advanced metastatic neuroendocrine tumours, it is still unclear if the combined therapy with PRRT and SSA can provide a prolonged survival compared to patients treated with PRRT alone.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Yordanova A

Authors: Yordanova A, Wicharz M, Gonzalez-Carmona M, Strassburg C, Mayer K,

Keywords: PRRT, SSA, combined therapy, survival,